Guzman J, Hilgarth M, Bross K J, Wiehle U, Ross A, Kresin V, Costabel U
Department of Pathology, University of Freiburg, Federal Republic of Germany.
Acta Cytol. 1988 Nov-Dec;32(6):811-5.
The aim of this study was to investigate lymphocyte subpopulations in 17 patients with malignant ascites due to serous papillary adenocarcinoma of the ovary. Eight patients had not been treated prior to the study whereas nine patients had been treated by surgery and chemotherapy. A panel of monoclonal antibodies against surface markers that correlate with the immune functions of the lymphocytes was used. The lymphocyte subpopulations were identified by the immunoperoxidase adhesive slide assay, and the results in treated and untreated patients were compared. Both groups of patients showed lymphocytosis (41 +/- 25% and 33 +/- 14% of the total cells, respectively). The untreated patients had a significantly higher proportion of B cells (14 +/- 4% of lymphocytes) than did treated patients (7 +/- 2%). No differences were found between both groups regarding the helper-inducer/suppressor-cytotoxic T lymphocyte ratio. The proportion of lymphocytes expressing interleukin-2-receptors was higher in treated patients (6 +/- 2%) than in untreated patients (1.2 +/- 1%). Both groups showed a high percentage of natural killer/cytotoxic cells (17 +/- 7% and 18 +/- 5%, respectively). In the only chylous effusion in this study, there was an increase in helper-inducer and activated T lymphocytes. Future studies are required to document whether surface marker analysis of lymphocytes in malignant effusions may be useful for assessment of the prognosis and the results of treatment.
本研究旨在调查17例卵巢浆液性乳头状腺癌所致恶性腹水患者的淋巴细胞亚群。8例患者在研究前未接受过治疗,而9例患者接受了手术和化疗。使用了一组针对与淋巴细胞免疫功能相关的表面标志物的单克隆抗体。通过免疫过氧化物酶黏附玻片试验鉴定淋巴细胞亚群,并比较治疗组和未治疗组患者的结果。两组患者均表现为淋巴细胞增多(分别占总细胞的41±25%和33±14%)。未治疗患者的B细胞比例(占淋巴细胞的14±4%)显著高于治疗患者(7±2%)。两组在辅助诱导/抑制细胞毒性T淋巴细胞比例方面未发现差异。表达白细胞介素-2受体的淋巴细胞比例在治疗患者中(6±2%)高于未治疗患者(1.2±1%)。两组均显示出较高比例的自然杀伤/细胞毒性细胞(分别为17±7%和18±5%)。在本研究唯一的乳糜性腹水中,辅助诱导和活化T淋巴细胞有所增加。未来需要开展研究,以证实对恶性腹水中淋巴细胞进行表面标志物分析是否有助于评估预后和治疗结果。